Roshan Karna, Resident Doctor at AIIMS, shared a post on LinkedIn:
“The Prostate Cancer Working Group 4 (PCWG4) recommendations represent a major advancement in the design and conduct of clinical trials in advanced prostate cancer. By transitioning from traditional castration-sensitive/castration-resistant terminology to an androgen pathway modulation (APMN/APMS/APMR) framework, PCWG4 aligns disease classification with contemporary therapeutic biology.
The integration of PSMA-PET into staging and progression assessment, refinement of PSA progression criteria, structured incorporation of molecular profiling (AR alterations, DNA repair defects, ctDNA, CTCs), and greater emphasis on patient-reported outcomes collectively move the field toward a truly biomarker-driven and patient-centric model. These updates also reflect closer alignment with regulatory science and precision oncology principles.
Clinical prostate cancer is evolving – more precise, more molecular, and more imaging-integrated than ever before.”
Other articles on OncoDaily.